Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2008

View Archived Issues

Novel plant-derived vaccine found safe and immunogenic in lymphoma patients

Efalizumab shows efficacy in the treatment of head and neck psoriasis

Pfizer's PF-3084014 effectively reduces Abeta levels in guinea pigs and mice

Novel fluorene compounds neutralize Abeta-oligomer toxicity in preclinical studies

Upregulation of Hsp70 by KU-32 leads to a reduction of Tau phosphorylation in mice

Mayo Clinic initiates dosing in phase Ib clinical study of Nile's CD-NP in heart failure

Bristol-Myers proposes to acquire ImClone Systems

Novel NS5B polymerase inhibitors described in recent patents

Novel oncolytic agents reported in patent literature

Upstream and Makerere University to collaborate on animal testing of Leishmaniasis treatment

Seattle Genetics commences phase I trial for SGN-70 in healthy volunteers

FDA issues not approvable letter to Schering-Plough for sugammadex

FDA grants orphan drug designation to afamelanotide in erythropoietic porphyrias

E.U. grants approval to Actelion's Tracleer in mildly symptomatic PAH

Karo Bio reports positive results from phase IIb study with eprotirome in dyslipidemia

Labopharm launches once-daily tramadol in South Korea, Australia, Romania and Austria

Aegera initiates dosing in phase I/II clinical oncology study of AEG-35156

BioMS completes enrollment in phase III MAESTRO-03 clinical trial of dirucotide

FDA awards RegeneRx additional USD 136,000 for phase II trial of RGN-137 in EB

Gilead and Merck & Co. sign agreement for HIV medication Atripla in 12 countries

PYY(3-36) for obesity does not meet primary efficacy endpoint in phase II study

Wyeth reviews Q2 highlights

Patents reveal discovery of compounds for metabolic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...